Recovery Kernel

[redacted]

Whole-Genome Sequencing [redacted] — [redacted]

[redacted]. [redacted]. [redacted]. [redacted].

⚠ [redacted]

[redacted] - [redacted], [redacted]. [redacted]. [redacted]: **14416 or 1800-89-14416** [redacted]. [redacted]: **112** [redacted]. **(GABRB3-[redacted]) GABA** [redacted] **—** [redacted].

[redacted] (Drugs.com, Medscape) [redacted].

□ □□□□ □□□□□□ □□□□□□□□□□□

□□□□□□□□□□□ □□□□□□ □□□□ □□□□□□□□□□□□□□□□□ □□□□□□□□□□ □□□ □□□□□□□□□□□ □□□□□□ □□□□□ □□□□□□□□□□□□□□□: □□□□ □□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□□ □□□□□□ □□□□□□□□□□□□□□, □□□□□□□□□□ □□□□□□□□□ □□□□□□□□□ □□□□□□□□□□ □□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□, □□□□□□□□□□□□□□□ □□□□□□ □□□□□ □□□□□□□□□□□ — □□□□□□□? □ □□□□ □ □□□□□□□□□□, □□□□□□□ □□□□□ □ □□□□□ □□□□□□□□□□□□□□□□ □□□□ □□□□□□□□□□□□□□□□□□□□

[illegible]	[illegible] [illegible] [illegible] [illegible]	[illegible] [illegible] [illegible]
30× [illegible] [illegible] [illegible] ([illegible], [illegible], [illegible].[illegible])	[illegible] [illegible]; [illegible] VCF [illegible] - [illegible] [illegible] [illegible]. ~$200–400, [illegible].	[illegible] [illegible] [illegible]. [illegible] [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] - [illegible] [illegible] [illegible] [illegible].
[illegible] [illegible] [illegible] (23andMe, Ancestry)	MTHFR, COMT, DRD2, [illegible] CYP [illegible] [illegible] ~700k [illegible] [illegible] SNP-[illegible] [illegible] .txt [illegible].	[illegible] [illegible] [illegible]. [illegible] VCF [illegible], [illegible] [illegible] [illegible]. [illegible] [illegible] (~$12) [illegible].
[illegible] [illegible] [illegible] [illegible] (CYP2D6/2C19/3A4 [illegible], [illegible] [illegible].	[illegible]/[illegible] [illegible] [illegible] [illegible]; [illegible] [illegible] WGS [illegible].
[illegible] [illegible] [illegible] ([illegible], [illegible]12, RBC [illegible])	[illegible] [illegible] [illegible]. [illegible] [illegible] [illegible] [illegible] [illegible].

[illegible] **+ : VCF** [illegible] [illegible] [illegible], [illegible] [illegible] **16** [illegible] **(**[illegible], [illegible]-[illegible], [illegible]-[illegible], [illegible], [illegible]-[illegible] [illegible]**)** [illegible]. [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]. [illegible] [illegible] [illegible]: [illegible] [illegible] [illegible] [illegible] — [illegible] [illegible] [illegible].

[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]. **CYP2D6** [illegible] **60-**[illegible] [illegible] [illegible] **FDA** [illegible] [illegible] **-** [illegible] [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible].

1[illegible]. [illegible] [illegible] [illegible] [illegible]: [illegible] [illegible] [illegible]

[illegible] [illegible]. [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] (1-[illegible] [illegible] 2/3 , [illegible] 06, [illegible] [illegible] [illegible]-[illegible] [illegible]). [illegible] [illegible] — [illegible] [illegible], [illegible] [illegible], [illegible] [illegible] — [illegible] [illegible] [illegible] 15 [illegible] [illegible] [illegible] [illegible]

[illegible] [illegible], [illegible]. [illegible] [illegible] [illegible] [illegible] [illegible] 60–80% [illegible] [illegible]; [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]. [illegible] [illegible], [illegible] [illegible] — [illegible] [illegible] [illegible] [illegible].

□□□□□ 2 — □□□ □□□ □□□□□□□□□□ □□□□□□□□□

□□□□□□□□□□ □□□□□□ □□□□□□□□□□□□; □□□□□□□□□□ □□□□□□. □□□ □□□ □□□□□□□□□□, □□□ □□□□□ □□□□□□□□ □□□□□ □□□□□□□□, □□□ □□□□□ □□□□□ □□□□□□□□□□ □□□□□□.

□□□□□□□□ 1 — MTHFR (□□□□□ □□□□□)

□□□□□□□□□□ □□□□□□□□□ □□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□ □□□□□□□□□□□□□ □□□□□ □□□□□□□□□□□□□ □□□□□□□□□ □□□□□ □□□□ □□□□□□□□□□□□□. □□□□ □□□□□□□□□□□□□□□ □□□□□□□□□ □□□□□□ □□□□□□□ □□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□. MTHFR □□□□□□□□ □□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□ - □□□ □□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□ □□□□□□□ □□□□□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□, □□□□□□□ ~40% □□□□□□□□□□ □□□□ □□□□□□□□□□□□□ □□□□□□□□□□ □□□□□□.

□□□	□□□□□□□	□□□ □□□□□□ □□□□□□□□□□□
□□/□□ (□□□□□□ □□□□□□□)	~100% □□□□□□□□□□□□.	□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□ □□□□□□□□□□□□ □□□□□□□□□□□; □□□□□□□□ □□□□□□□□□ □□□□□□□.
C/T (□□□□□□□□□□□□□□□□)	~60–65% □□□□□□□□□□□□.	□□□□□□□□□□□□□□□ □□□□□□□□□□□□□ □□□□□□□□□□□□□, □□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□.
T/T (□□□□□□□□□□□□)	~30–40% □□□□□□□□□□□□; □□□□□□□□□ □□□□□□□.	□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□ □□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ - □□□ □□□□□□□□, □□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□ □□□□□□□□.
□□□□□□□□□□ □□□□□□□ (C/T + A1298C A/C)	□□□□□□□ □□□□□□□□□□□□□□□□; T/T □□□□□ □□□□□□□□□□□□□□.	□□□□□□□□□□□□□□□□□□□ □□/□□ □□□□ □□□□□□□□□□□□□.

MTHFR □□□□□□ □□□□□□□□□□

□□□□□□□□□□□ **T** □□□□□□□□□□ **→** □□□□□□□□□□□□ □□□□□□□ □□□□□□ **(**□□□□□□□□□□ □□□□□□ □□□□□□□□□□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□**)** □□□□□□□□□□□□. □□□□□□□□□□ □□□□□□□□□ □□□□□□□ □□□□□□□□□□; □□□□ □□□□□□□□□□□□□ □□□□□□□□□ □□□□□□□□□ □□□□□□□□□□□ □□□□□□□□□□ □□□□□□□□□ □□□□□□□□□□□□□□□□□□□□

□□□□	□□□□□□□□	□□□□□ □□□□□□□□□ **(Substance use) □□□□□□□□□□□□ (recovery)** □□□□□□□□□□□
Val/Val	□□□□□□□ - □□□□□□□□□□□□□□ □□□□□□□□□□□□□□	□□□□□□□□ □□□□□□□□□; □□□□□□□ □□□□□□□ □□□□□□□□□□□ □□□□□□□□□□□. □□□□□□□□□□□□□□ □□□□ □□□□□□□□□. □□□□□□□□□□□, □□□□□□□□□□□ □□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□.
□□□□□□□/□□□□□□□	□□□□□ / □□□□□□□□□□□□□□□ — □□□□□□□□□□□□□□□□□ □□□□□□□□□□	□□□□□□□□□ □□□□□□□□□□□ □□□□□□□□□□□□□ □□□□□□□□□□. □□□□□□□□□□□ □□□□□□□ □□□□□□□□□□□□□□. □□□□□□□, □□□□, □□□□□□□ □□□□□□□□□ □□□□□□□ □□□□□□□□□□□ - □□□□□□□ □□□□□□□□□□□□.
Val/Met	□□□□□□□□□□□□□□	□□□□□□□□□□□□□□; □□□□□□□□□ □□□□□□□□□□□□□ □□□□□□ □□□□□□□□□□□□□□□□□□□□ □□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□.

□ □□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□ □□□□□□ □□□□□□ □□□□□□□□□□□□□□□□□□□□

[illegible] [illegible]-[illegible] [illegible], [illegible] [illegible] [illegible] [illegible]. GABRA2 [illegible] [illegible] [illegible] - [illegible] [illegible] '[illegible]' [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]. [illegible] [illegible]; [illegible] [illegible] [illegible]. [illegible], [illegible] [illegible] - [illegible] [illegible] [illegible] [illegible].

[illegible]	[illegible]	[illegible] [illegible] [illegible]
GABRA2 [illegible] [illegible] (rs279858 T-[illegible]) — ~15–20%	[illegible] [illegible]. [illegible] [illegible] [illegible] [illegible] [illegible].	[illegible]/[illegible] '[illegible] [illegible] [illegible]' [illegible] [illegible]. [illegible]-[illegible] [illegible]. [illegible] [illegible] [illegible].
GABRA2 [illegible]-[illegible] — ~30–35%	[illegible] [illegible].	[illegible] [illegible] [illegible]; [illegible] [illegible] [illegible] [illegible].
GABRB3 [illegible] [illegible]	[illegible] [illegible]; [illegible] [illegible] [illegible] [illegible] [illegible].	[illegible]/[illegible] [illegible] [illegible] - [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]. [illegible] [illegible], [illegible].

[illegible] [illegible] [illegible] [illegible]?

[illegible] [illegible] [illegible] [illegible]. [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]. **GABRA2** [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] — [illegible] [illegible] [illegible] [illegible].

[illegible] [illegible]: **GABRA2** [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] — [illegible] [illegible], [illegible] [illegible], [illegible] [illegible]. [illegible] [illegible] [illegible] [illegible]: [illegible] [illegible] [illegible] [illegible] [illegible] [illegible], [illegible], [illegible], [illegible], [illegible] [illegible] [illegible]), [illegible] [illegible] [illegible] [illegible], [illegible].

[illegible] 5 — OPRM1 [illegible] DRD2 [illegible] ([illegible] [illegible])

- **OPRM1 A118G.** [illegible]-[illegible] [illegible] [illegible] **(AG/GG)** [illegible] [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] — [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible].

- **DRD2 Taq1A (□□□□□□□□ □□□□□□). A1** □□□□ □□□□□□□ **~30%** □□□□□□□ **D2** □□□□□□□□□□□□□□□□□□□□□□□ **—** □□□□□□□ □□□□□□□□□□□ □□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□ □□□□□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□□□□ □□□□□□□□□□□□ □□□□□□□□ □□□□□□. □□□□□□□□□□□□□□□□□□□□

[illegible] 3 — [illegible] [illegible] [illegible] [illegible]

[illegible] [illegible] [illegible] - [illegible]. [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]. [illegible] [illegible]-[illegible] [illegible] [illegible] [illegible] [illegible] [illegible].

[illegible] [illegible]	[illegible]	[illegible] & [illegible] [illegible]
[illegible] [illegible] — MTHFR T/T + COMT Met/Met	[illegible] [illegible] + [illegible]	[illegible] [illegible] [illegible]. [illegible] [illegible]/[illegible]/[illegible] [illegible] [illegible], [illegible]. [illegible]: [illegible] 15mg, маг[illegible] 800mg, SAMe 800mg, [illegible], [illegible] [illegible].
[illegible] [illegible] [illegible] [illegible] — MTHFR T/T + COMT Val/Val	[illegible] [illegible] + [illegible]	[illegible], [illegible], [illegible] [illegible]. [illegible] [illegible] '[illegible] [illegible]'. [illegible]: [illegible] 7.5mg, [illegible], [illegible], [illegible], [illegible] [illegible] [illegible].
[illegible] [illegible] — CYP2D6 PM/UM + MTHFR/COMT	[illegible] [illegible] + [illegible]	[illegible] [illegible] '[illegible]'[illegible] [illegible] [illegible] [illegible]. [illegible] [illegible] (CYP2D6-[illegible]). [illegible]: [illegible]; Naloxone [illegible].
[illegible] [illegible] — GABRA2 + COMT Val/Val	[illegible] [illegible] + [illegible]	[illegible] [illegible] [illegible]; [illegible] [illegible]. [illegible]: [illegible] [illegible] + [illegible]- [illegible] [illegible] + [illegible]- [illegible].
[illegible] [illegible] — GABRA2 + COMT [illegible]/[illegible]	[illegible] [illegible] + [illegible] [illegible]	[illegible] [illegible]. [illegible]: [illegible] [illegible] + [illegible]; [illegible] [illegible] [illegible].
Depleted-Impulsive — GABRA2 + MTHFR T/T	[illegible] [illegible] + [illegible]	[illegible] [illegible] [illegible] [illegible]: [illegible] [illegible].

[illegible] [illegible]	[illegible]	[illegible] & [illegible] [illegible]
	[illegible]	[illegible] [illegible].

[illegible] [illegible] [illegible]

[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]: **MTHFR-[illegible] →** [illegible] [illegible] [illegible]. **COMT Val/Val →** [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]. **COMT Met/Met →** [illegible] [illegible] [illegible] [illegible]. **GABRA2 →** [illegible] [illegible]. **CYP2D6 [illegible]-[illegible] →** [illegible] [illegible] [illegible] **Naloxone** [illegible] [illegible]. **DRD2 A1 →** [illegible] [illegible] [illegible] [illegible] [illegible]. [illegible] **4–5** [illegible] [illegible] [illegible] [illegible] [illegible]

[illegible] 4 — [illegible]

[illegible]-[illegible] [illegible] [illegible] [illegible]: [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]. [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

□□□□□□□□□□□□□ □□□□ □□□□□□□□□□ — □□□□□□□□ □□□□□□□□□□□□ □□□□□□□□□□,
□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□.

□□□□□□□□□ □□□□□□□□□□□ □□ - □□□□□□□□□ (□□□□ □□□□□□□□□□-□□□□□□□ □□□□□□□□□□□□□)

□□□□□□□□□□□: 7-□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□ □□□□□□ □□□□□-□□□□□□□□ □□□□□□□□□□□□□ □□□□. □□□□□□□□□□ □□□□□□□□ □□□□□□□□□□□□□□□□□□□□ - □□□□□□□□□□□□, □□□□□□□□□□□□, 12–24 □□□□□□□□□□ □□□□□□. □□□□□□□□□□ □□□□□□□□□□□□□□□□□ □□□□□□□□□□□ □□□□□□□□ □□□□□□□□□□□□□ □□□□□ □□□□□□□□□□□□□□□□□□□□ □□□□□ □□□□□ / □□□□□□□□□□□□□ □□□□□□□□□□□□ □□□□ □□□□□□□□□□ □□□□□□□□□□□□□□□□.

- **COMT Met/Met,** □□□□□□□□□□ **+ MTHFR T/T; OPRM1, CYP2D6** □□□□□□□□□□□□ □□□□ □□□□□□□□□□□□□□ □□□□□□□ □□□□□□□□□□□□□.
- □□□□□□□/□□□□□□□□□□ **—** □□□□□□□ □□□□□□□□: □□□□□□□□□□□□□□ □□□□□□□□□□□ □□□□ □□□□□□□□□ □□□□□□□□□□□□□, □□□□□□□□□□□ □□□□□□□□□□, □□□□□□□ □□□□ □□□□□□□□ □□□□□□□ **MAT** □□□□□□□□□□□□□□□□□□ □□□□□ □□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□. **OPRM1 G-**□□□□□□□□ □□□□□□□□□, □□□□□□□□□□□□□□□ □□□□□□□□□□□ □□□□□□□□□□□□□, □□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□. **DLPA** □□□□□□□□□□, **5–10%** □□□□□□□□□ □□□□□□□□□ □□□□□□.
- □□□□□□□□ □□□□□□□□□□□: □□□□□ □□□□□□□□□□ **—** □□□□□□□□□□□□□□□□, **маг**□□□□□, **SAMe,** □□□□□□□□ □□□□□□□ □□□□□□□□□□□ □□□□□□□□□□□□□□ □□□□□□□ □□□□□□; □□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□

[illegible] 5 — [illegible], [illegible], [illegible]

[illegible] [illegible] [illegible] [illegible]. [illegible] [illegible] [illegible], [illegible] [illegible] [illegible], [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible].

[illegible] [illegible] — [illegible] [illegible] ([illegible] 1–3)

[illegible] [illegible] [illegible] [illegible] [illegible]. [illegible] 8 [illegible] [illegible] [illegible] — [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] (B12, [illegible]) [illegible].

[illegible] [illegible] (MTHFR [illegible])

- [illegible]-[illegible]: 1[illegible] [illegible] → 8 [illegible] 7.5–15[illegible] (MTHFR [illegible] [illegible])
- [illegible] (B12) 5,000mcg · [illegible] 400–800mg · [illegible]-5-[illegible] (B6) 50mg · TMG 1,000mg
- [illegible]-3 (EPA/DHA) 2–3[illegible] • NAC 1,200[illegible] ([illegible] [illegible]) • [illegible] 1,000[illegible]

[illegible] [illegible] (COMT Val/Val)

- [illegible] 1,000–2,000mg · [illegible] 200–400mg · [illegible] 500mg 2×/[illegible] · [illegible] [illegible] 400mg

[illegible]/[illegible] [illegible] (COMT [illegible]/[illegible])

- [illegible] 400mg [illegible] 2 [illegible] · SAMe 800mg · [illegible] 1,000mg · [illegible]

[illegible] [illegible] (GABRA2/GABRB3 [illegible])

- [illegible] 600–800mg [illegible] ([illegible]) · [illegible] 400mg [illegible] 2 [illegible] · [illegible] 1,000mg · [illegible] 3g · [illegible] [illegible] [illegible] ([illegible]). [illegible]: [illegible]/[illegible], [illegible], KSM-66 [illegible].

[illegible] [illegible] — [illegible] [illegible] [illegible] [illegible] ([illegible] 3–6)

[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]. [illegible] [illegible] [illegible] [illegible]:

- [illegible]/[illegible]: [illegible] **MAT** [illegible]; [illegible] **1-2** [illegible] **5–10%** [illegible]; **DLPA 500mg 2×/[illegible]**; [illegible] [illegible] [illegible].
- [illegible]/[illegible]: [illegible] **([illegible])**; [illegible] **2** [illegible] **2,000mg** [illegible]; [illegible] [illegible] [illegible].
- [illegible]/[illegible] **([illegible] GABRB3-[illegible])**: [illegible] — [illegible] [illegible].

□□□□□ □□□□□□□□, □□□□□□□□□ □□□□□□□□□□□□□ □□□□□□□□□□□□□. **GABA □□□□□□□□ (□□□□□□□, □□□□□□, мar□□□□□□□□, □□□□□□□□); □□□□□□□□□ □□□□□□□□□□□□□□□□□□□□ □□□□□□□□ □□□□□ □□□□□□□ □□□□□□□□□□□□□□/□□□□□□□□□□.**

□□□□□ □□□□□□ — □□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□ (□□□□ 6–12)

□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□, □□□□□□ □□□□□□□□ □□□□□□□□□□□ □□□□□□□□□□□ □□□□ □□□□□□□□□□□ □□□□□□□□□□□□ (BDNF, D2 □□□□□□□□□, □□□□□□□□□□□ □□□□□□□□□□□□□□) — □□□□ □□□□□□□□□□ □□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□.

	□□□□□□□ (Val/Val)	□□□□□/□□□□□□ (□□□□□□□/□□□□□□□)	GABRA2 (□□□□□□□□□ □□□□□□□□□□□□)
□□□□□□□ □□	HIIT, □□□□□□, □□, □□ □□□□	□□□, □□□-2 □□□□□□□□, □□□□□□□, □□□□□□□	□□□□□□□□□ □□□□□□□□ (□□□□□□□□□□/□□□□ □□□□□ □□□□□□□ □□□□□□□□□□□ □□□□□□□□□□), □□□-2 □□□□□□□□, 4-7-8 □□□□□□□.
□□□□□□□□ □□□	□□□□□□□□□□□□□ □□□□□ □□□□□□□□ → □□□□□□□□□□□□□□	HIIT/□□□□□ □□□□□□□ → □□□□□□□□□□□ □□□□□□□□□□□□□	□□□□□□ □□□□ □□□□□□□□□ □□□□□□□□□□□□□□□□□□□□ □□□□□□□ □□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□
□□□□□□□ □□	□□□□□□□□□□□□□ □□□□ □□□□□	□□□□□□□□□□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□□□ □□□□ □□□□□□ □□□□□□	□□□□□□□□□□□□□ □□□□□□□□ □□□□; □□□□□□□ □□□□□□□□□ □□□□□□□□□□□

□□□□□□□□ □□□□□□□ - □□□□□□□□□ □□□□□□□□ □□□□□□□□□□□□□□□ **('□□□□□□□□□□ □□□□□□□' □□□□□□□□□)**

□□□□□□□ □□□□□□□□□ □□□□□□□□□□□ □□□□□□□□□ □□□□□□□□□□□ □□□□□ □□□□□□□□□□□□□□□□□□□ □□ □□□□□□□□ □□□□□□□□□□□□□□□□□□□□. □□□□□□□□□□ □□□□□□□□□□□□□ □□□□□□□□□□□□□□□□, □□□□□□□□□□□□□□□□□ □□□□□ □□□□□□□□□□□□□□□□□□□□□□: '□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□ □□□□□ □□□□□□□□□□□□□□□□□□□□□' □□□□□□□ **4–8** □□□□□□□□□□ □□□□□□□□□□; '**8-**□□□□□□□□□ □□□□□□□ □□□□□' □□□□□□□ **2–5** □□□□□□□□□ □□□□□□□ □□□□□□ □□□□□□□□ □□□□□□□□□□□□□□□□□□□□ **12–16** □□□□□□□□□□ □□□□□□□□□. □□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□ □□□□□□□ □□□□□□□□□□□□□ □□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□

[illegible] 6 — [illegible] [illegible] [illegible] [illegible]

[illegible] [illegible] [illegible] [

[illegible]

[illegible] → [illegible] [illegible] [illegible]